Page 1 of 4
1234

2024 (2 POSTS)

Perry CS, Verwiel AH, Covington TR, Proctor DM. 2024. PBPK modeling demonstrates that exposure time adjustment is unnecessary for setting an acute manganese inhalation exposure guideline. Regul Toxicol Pharmacol 153(Nov):105698; doi: 10.1016/j.yrtph.2024.105698. PMID: 39251127.

View Abstract

Mittal L, Perry CS, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Anal. 44(9):2169-2186. doi: 10.1111/risa.14309. PMID: 38622492.

View Abstract

2023 (2 POSTS)

Covington TR, Sterner TR. Physiologically-based pharmacokinetic model to predict HFC-134a in exhaled breath following albuterol inhaler use. Poster presented at the Society of Toxicology Annual Meeting, Nashville, TN, March 2023.

Sterner TR, Covington TR, Mattie DR. 2023. Complex mixtures: Array PBPK modeling of jet fuel components. Toxics 11(2):187; doi: 10.3390/toxics11020187. PMID: 36851061.

View Abstract

2022 (1 POST)

Pouillot R, Farakos SS, Spungen J, Schaefer HR, Flannery BM, Van Doren JM. 2022. Cadmium physiologically based pharmacokinetic (PBPK) models for forward and reverse dosimetry: Review, evaluation, and adaptation to the U.S. population. Toxicol Lett 367(Aug):67-75; doi: 10.1016/j.toxlet.2022.07.812. PMID: 35901988. Corrigendum: Toxicol Lett 2023 377(March):14-15; doi: 10.1016/j.toxlet.2023.01.011.

View Abstract

2020 (1 POST)

Covington TR, Gearhart JM. 2020. Sensitivity and Monte Carlo analysis techniques and their use in uncertainty, variability, and population analysis. In: Fisher JW, Gearhart JM, Lin Z (eds), Physiologically Based Pharmacokinetic (PBPK) Modeling, pp. 211–242. Academic Press.

2019 (1 POST)

Yoon M, Ring C, Van Landingham CB, Suh M, Song G, Antonijevic T, Gentry PR, Taylor MD, Keen AM, Andersen ME, Clewell JH. 2019. Assessing children’s exposure to manganese in drinking water using a PBPK model. Toxicol Appl Pharmacol 380(Oct 1):114695; doi: 10.1016/j.taap.2019.114695.

View Abstract

2018 (1 POST)

Covington TR, Ott DK, Gearhart JM, Pangburn HA. A physiologically-based pharmacokinetic model to address physiological changes associated with high-performance aircraft flight. Presentation at the Annual Meeting of the Military Health System Research Symposium, Orlando, FL, August 2018.

2017 (2 POSTS)

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

View Abstract

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

2016 (2 POSTS)

Covington TR, Lumley LA, Ruark CD, Clarkson ED, Whalley CE, Gearhart JM. 2016. Modeling organophosphorus chemical warfare nerve agents: A physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) model of VX. In: Worek F, Jenner J, Thiermann H (eds), Chemical Warfare Toxicology: Volume 1: Fundamental Aspects, pp. 213–263. Royal Society of Chemistry.

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

View Abstract

2015 (1 POST)

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

2014 (2 POSTS)

Kirman CR, Proctor D, Suh M, Thompson CM, Harris MA, Haws LC, Hays SM. Variation analysis of PBPK model parameters for describing the delivery of Cr(VI) to the small intestines of humans. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

View Abstract

Hack CE, Covington TR, Robinson PJ, Shiyanov PA, Mahle DA, Gearhart JM. A PBPK model of hypobaric and hyperbaric toluene exposure. Poster presented at the Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

2013 (4 POSTS)

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CMHaws LCProctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

View Abstract

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

View Abstract

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Sterner TR, Ruark CD, Covington TR, Yu KO, Gearhart JM. 2013. A physiologically based pharmacokinetic model for theoxime TMB-4: Simulation of rodent and human data. Arch Toxicol 87:661680; doi: 10.1007/s00204-012-0987-z.

View Abstract

2012 (1 POST)

Knutsen JS, Kerger BD, Finley BL, Paustenbach DJ. 2012. A calibrated human PBPK model for benzene inhalation with urinary bladder and bone marrow compartments. Risk Anal 33 (7):1237–1251; doi: 10.1111/j.1539-6924.2012.01927.x. PMID: 23278103.

View Abstract
Page 1 of 4
1234